UCLA scientists disclosed an affordable blood test, MethylScan, designed to detect multiple cancers and liver disorders simultaneously by analyzing cell-free DNA methylation patterns. The approach targets tissue-specific DNA methylation signatures in cfDNA, aiming to provide an alternative to mutation-focused liquid biopsies. The work reports early studies in more than 1,000 people and is published in the Proceedings of the National Academy of Sciences (PNAS). The technology is positioned as a “high-signal” signal readout for organs, leveraging the fact that cfDNA fragments in blood originate from diverse tissues. The scientific premise is that methylation patterns shift with cancerous or diseased states, potentially allowing broad screening and clinical monitoring rather than focusing on a limited set of tumor mutations. For diagnostics companies and translational researchers, the central development is a multi-indication cfDNA methylome assay framework that aims to reduce cost and complexity relative to deep sequencing-heavy tests.